Journal Information
Vol. 43. Issue. 1.January - February 2023
Pages 1-160
Vol. 43. Issue. 1.January - February 2023
Pages 1-160
Letter to the Editor
Full text access
Comments on “Nonvalvular atrial fibrillation in patients undergoing chronic haemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?”
Comentarios a «Fibrilación auricular no valvular en pacientes en hemodiálisis crónica. ¿Debemos anticoagular?»
Visits
1134
Aleix Casesa,b,c, José Jesús Brosetac,
Corresponding author
jjbroseta@clinic.cat

Corresponding author.
, Diana Rodriguez-Espinosac, José Luis Górrizd,e,f
a Universitat de Barcelona, Barcelona, Spain
b Institut d’Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
c Servicio de Nefrología y Trasplante Renal, Hospital Clínic de Barcelona, Barcelona, Spain
d Servicio de Nefrología, Hospital Clínico Universitario, Valencia, Spain
e INCLIVA, Valencia, Spain
f Universitat de València, Valencia, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

It was with interest that we read “Non-valvular atrial fibrillation in patients undergoing chronic haemodialysis. Should we anti-coagulate?”,1 and we found it engaging and up-to-date, but we want to make some observations.

Thrombotic risk assessment to indicate anti-coagulation in patients with atrial fibrillation (AFib) in the general population has been based on the CHA2DS2-VASc. However, data from the recent SCREAM study call the validity of this score into question across the spectrum of chronic kidney disease (CKD), proposing the use of the modified CHADS.2 In dialysis patients, de Vriese et al. alternatively propose the "dialysis risk score", which includes prior stroke or transient ischaemic attack, diabetes, age >75 years, and gastrointestinal bleeding,3 which would drastically reduce the indication for anti-coagulation in these patients, although its validation is required. The authors comment on the poor predictive value of the bleeding risk of the scores used on the general population of hemodialysis, and mention the CHA2DS2-VASc.1 This does not measure the risk of bleeding, nor is it analysed in the referenced study, which may lead to confusion.

Regarding treatment with coumarins or vitamin K antagonists (VKA), the authors mention the risk of vascular calcification and arterial stiffness,1 which is correct, but it should be noted that they also increase the risk of peripheral vascular disease, valve calcification or calciphylaxis (already prevalent in this population), which calls into question their safety profile in dialysis.4,5

We agree with the authors that the time in therapeutic range (TTR) is low in patients with CKD,1 and especially those on haemodialysis, as demonstrated by clinical trials (CT) (Renal-AF or Valkyrie), in which better control of this is assumed, as well as in numerous observational studies. A worse TTR is associated with a higher risk of stroke or death,6 so nephrologists should be more involved and be aware of the TTR of our patients being treated with VKA so we can proactively suggest other therapeutic alternatives if this is unsatisfactory. Furthermore, an Italian group proposes that the variability of the international normalised ratio (INR) (high in this population) would be a better marker of mortality and risk of bleeding.7 In fact, de Vriese et al. propose that anti-coagulation in patients with AFib on dialysis should be done with apixaban or rivaroxaban for this reason, among others.3

Regarding the CTs with VKA vs no anti-coagulation in dialysis patients with AFib, in addition to the aforementioned AVKDIAL, the Danish Warfarin-Dialysis Study Safety and Efficacy of Warfarin in Patients with Atrial Fibrillation on Dialysis (DANWARD) (NCT03862859) is underway. Both studies will provide valuable information on the risk-benefit of VKAs in dialysis patients, which has been questioned by observational studies and meta-analyses.8,9

Regarding the comments made about warfarin-related nephropathy, this has a clear definition; acute kidney injury after an INR>3. Anticoagulant-related nephropathy has had its definition extended to include direct oral anti-coagulants (DOACs), with which it has also been described (although less frequently than with VKAs) in patients with underlying kidney disease.10 This should be differentiated and not confused with the more rapid deterioration of kidney function associated with VKA and recognised even in clinical guidelines11 and whose cause is probably multifactorial, according to the review by Gómez-Fernández et al.10

Regarding DOACs, apixaban and rivaroxaban seem to be alternatives to classical oral anti-coagulation, although some observational studies question the benefit of DOACs vs no anti-coagulation in this population, which needs to be demonstrated.12 The Valkyrie study, mentioned in the article, has demonstrated a reduction in cardiovascular events with rivaroxaban 10mg/day vs VKA (including fewer peripheral vascular events) with a better safety profile. Therefore, to date it is the only clinical trial that has demonstrated a better risk-benefit profile in this population, pending the results of the two studies with apixaban (AXADIA and SAFE-D) mentioned by the authors.1

Finally, although percutaneous left atrial appendage closure (LAAC) is an attractive alternative to oral anti-coagulation to prevent thromboembolic events in dialysis patients, as demonstrated by the study by Genovesi et al.13 mentioned in the article; a recent analysis of a LAAC registry with a much larger sample found higher mortality during hospitalisation and a trend towards increased mortality in the sub-group of dialysis patients.14

Therefore, anti-coagulant treatment in dialysis patients with AFib will remain a controversial issue due to the scant evidence from CT, starting with the selection of patients who may benefit from it. This requires a greater involvement of the nephrologist in the indication and follow-up of oral anticoagulation and, consideration of the alternative of DOACs (limited by approval for dialysis by the EMA), to avoid/reduce the risks associated with VKAs, and consideration of LAAC as an option, but carefully assessing the risk-benefit profile.

Funding

The authors declare that they have not received funding for this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
C. Sánchez-González, J.A. Herrero Calvo.
Fibrilación auricular no valvular en pacientes en hemodiálisis crónica. ¿Debemos anticoagular?.
[2]
Y. de Jong, E.L. Fu, M. van Diepen, M. Trevisan, K. Szummer, F.W. Dekker, et al.
Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function.
Eur Heart J, 42 (2021), pp. 1476-1485
[3]
A.S. de Vriese, G. Heine.
Anticoagulation management in hemodialysis patients with atrial fibrillation: evidence and opinion.
Nephrol Dial Transplant, (2021),
[4]
K.H. Lee, S.Y. Li, J.S. Liu, C.T. Huang, Y.Y. Chen, Y.P. Lin, et al.
Association of warfarin with congestive heart failure and peripheral artery occlusive disease in hemodialysis patients with atrial fibrillation.
J Chin Med Assoc, 80 (2017), pp. 277-282
[5]
L. di Lullo, G. Tripepi, C. Ronco, G. D’Arrigo, V. Barbera, D. Russo, et al.
Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor.
Int J Cardiol, 278 (2019), pp. 243-249
[6]
C.L. Morgan, P. McEwan, A. Tukiendorf, P.A. Robinson, A. Clemens, J.M. Plumb.
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.
Thromb Res, 124 (2009), pp. 37-41
[7]
P. Rebora, M. Moia, M. Carpenedo, M.G. Valsecchi, S. Genovesi.
Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation.
Blood Transfus, 19 (2021), pp. 487-494
[8]
T. Kuno, H. Takagi, T. Ando, T. Sugiyama, S. Miyashita, N. Valentin, et al.
Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis.
J Am Coll Cardiol, 75 (2020), pp. 273-285
[9]
M.S. Randhawa, R. Vishwanath, M.P. Rai, L. Wang, A.K. Randhawa, G. Abela, et al.
Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis.
[10]
P. Gómez-Fernández, A. Martín Santana, J.D. Arjona Barrionuevo.
Oral anticoagulation in chronic kidney disease with atrial fibrillation.
Nefrologia, 41 (2021), pp. 137-153
[11]
C.T. January, L.S. Wann, H. Calkins, L.Y. Chen, J.E. Cigarroa, J.C. Cleveland Jr, et al.
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol, 74 (2019), pp. 104-132
[12]
L.C. See, H.F. Lee, T.F. Chao, P.R. Li, J.R. Liu, L.S. Wu, et al.
Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis.
Cardiovasc Drugs Ther, 35 (2021), pp. 975-986
[13]
S. Genovesi, A. Vincenti, E. Rossi, D. Pogliani, I. Acquistapace, A. Stella, et al.
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.
Am J Kidney Dis, 51 (2008), pp. 255-262
[14]
K.R. Ahuja, R.W. Ariss, S. Nazir, R. Vyas, A.M. Saad, M. Macciocca, et al.
The association of chronic kidney disease with outcomes following percutaneous left atrial appendage closure.
JACC Cardiovasc Interv, 14 (2021), pp. 1830-1839
Copyright © 2022. Sociedad Española de Nefrología
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?